Annual FCF
-$145.76 M
+$25.75 M+15.01%
31 December 2023
Summary:
Adaptimmune Therapeutics annual free cash flow is currently -$145.76 million, with the most recent change of +$25.75 million (+15.01%) on 31 December 2023. During the last 3 years, it has fallen by -$89.26 million (-158.00%). ADAP annual FCF is now -510.95% below its all-time high of $35.47 million, reached on 30 June 2014.ADAP Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$54.89 M
-$101.53 M-217.67%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly free cash flow is currently -$54.89 million, with the most recent change of -$101.53 million (-217.67%) on 30 September 2024. Over the past year, it has dropped by -$9.44 million (-20.77%). ADAP quarterly FCF is now -142.26% below its all-time high of $129.89 million, reached on 31 December 2021.ADAP Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$56.05 M
-$9.44 M-20.25%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM free cash flow is currently -$56.05 million, with the most recent change of -$9.44 million (-20.25%) on 30 September 2024. Over the past year, it has increased by +$75.59 million (+57.42%). ADAP TTM FCF is now -2977.41% below its all-time high of $1.95 million, reached on 31 December 2021.ADAP TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.0% | -20.8% | +57.4% |
| 3 y3 years | -158.0% | -17.1% | +64.6% |
| 5 y5 years | -33.6% | -83.3% | +58.3% |
ADAP Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -7582.6% | +15.0% | -142.3% | +10.8% | -2977.4% | +67.3% |
| 5 y | 5 years | -7582.6% | +15.0% | -142.3% | +10.8% | -2977.4% | +67.3% |
| alltime | all time | -510.9% | +15.0% | -142.3% | +10.8% | -2977.4% | +67.3% |
Adaptimmune Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$54.89 M(-217.7%) | -$56.05 M(+20.2%) |
| June 2024 | - | $46.65 M(-244.4%) | -$46.61 M(-66.3%) |
| Mar 2024 | - | -$32.31 M(+108.4%) | -$138.26 M(-5.1%) |
| Dec 2023 | -$145.76 M(-15.0%) | -$15.50 M(-65.9%) | -$145.76 M(+10.7%) |
| Sept 2023 | - | -$45.45 M(+1.0%) | -$131.64 M(-9.0%) |
| June 2023 | - | -$45.00 M(+13.1%) | -$144.59 M(-3.5%) |
| Mar 2023 | - | -$39.80 M(+2771.9%) | -$149.80 M(-12.7%) |
| Dec 2022 | -$171.51 M(-8904.4%) | -$1.39 M(-97.6%) | -$171.51 M(+326.2%) |
| Sept 2022 | - | -$58.40 M(+16.3%) | -$40.24 M(+40.1%) |
| June 2022 | - | -$50.21 M(-18.4%) | -$28.71 M(+144.5%) |
| Mar 2022 | - | -$61.52 M(-147.4%) | -$11.74 M(-702.8%) |
| Dec 2021 | $1.95 M(-103.4%) | $129.89 M(-377.1%) | $1.95 M(-101.2%) |
| Sept 2021 | - | -$46.87 M(+41.0%) | -$158.39 M(+23.1%) |
| June 2021 | - | -$33.24 M(-30.5%) | -$128.64 M(+6.5%) |
| Mar 2021 | - | -$47.83 M(+57.1%) | -$120.83 M(+113.9%) |
| Dec 2020 | -$56.50 M(-51.1%) | -$30.45 M(+77.9%) | -$56.50 M(+44.2%) |
| Sept 2020 | - | -$17.12 M(-32.7%) | -$39.19 M(-24.7%) |
| June 2020 | - | -$25.44 M(-254.0%) | -$52.01 M(-15.8%) |
| Mar 2020 | - | $16.51 M(-225.7%) | -$61.76 M(-46.6%) |
| Dec 2019 | -$115.58 M | -$13.14 M(-56.1%) | -$115.58 M(-14.0%) |
| Sept 2019 | - | -$29.95 M(-14.9%) | -$134.34 M(+40.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$35.18 M(-5.7%) | -$95.80 M(-1.5%) |
| Mar 2019 | - | -$37.31 M(+17.0%) | -$97.22 M(-10.9%) |
| Dec 2018 | -$109.10 M(+37.5%) | -$31.90 M(-471.0%) | -$109.10 M(+8.6%) |
| Sept 2018 | - | $8.60 M(-123.5%) | -$100.48 M(+3.4%) |
| June 2018 | - | -$36.60 M(-25.6%) | -$97.22 M(+11.0%) |
| Mar 2018 | - | -$49.19 M(+111.2%) | -$87.59 M(+10.4%) |
| Dec 2017 | -$79.33 M(+30.1%) | -$23.29 M(-296.3%) | -$79.33 M(+30.9%) |
| Sept 2017 | - | $11.86 M(-144.0%) | -$60.59 M(-32.6%) |
| June 2017 | - | -$26.97 M(-34.1%) | -$89.91 M(+11.5%) |
| Mar 2017 | - | -$40.93 M(+799.4%) | -$80.64 M(+32.3%) |
| Dec 2016 | -$60.95 M(+118.5%) | -$4.55 M(-73.9%) | -$60.95 M(+8.1%) |
| Sept 2016 | - | -$17.46 M(-1.3%) | -$56.40 M(+22.4%) |
| June 2016 | - | -$17.70 M(-16.7%) | -$46.07 M(+62.4%) |
| Mar 2016 | - | -$21.25 M(+198.1%) | -$28.38 M(+169.0%) |
| Dec 2015 | -$27.90 M(-19.7%) | - | - |
| Sept 2015 | - | -$7.13 M(+108.3%) | -$10.55 M(-38.1%) |
| June 2015 | -$34.75 M(-198.0%) | - | - |
| Dec 2014 | - | -$3.42 M(-74.9%) | -$17.05 M(+25.1%) |
| Sept 2014 | - | -$13.62 M | -$13.62 M |
| June 2014 | $35.47 M(-547.6%) | - | - |
| June 2013 | -$7.92 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual free cash flow?
- What is the all time high annual FCF for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual FCF year-on-year change?
- What is Adaptimmune Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly FCF year-on-year change?
- What is Adaptimmune Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM FCF year-on-year change?
What is Adaptimmune Therapeutics annual free cash flow?
The current annual FCF of ADAP is -$145.76 M
What is the all time high annual FCF for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual free cash flow is $35.47 M
What is Adaptimmune Therapeutics annual FCF year-on-year change?
Over the past year, ADAP annual free cash flow has changed by +$25.75 M (+15.01%)
What is Adaptimmune Therapeutics quarterly free cash flow?
The current quarterly FCF of ADAP is -$54.89 M
What is the all time high quarterly FCF for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly free cash flow is $129.89 M
What is Adaptimmune Therapeutics quarterly FCF year-on-year change?
Over the past year, ADAP quarterly free cash flow has changed by -$9.44 M (-20.77%)
What is Adaptimmune Therapeutics TTM free cash flow?
The current TTM FCF of ADAP is -$56.05 M
What is the all time high TTM FCF for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM free cash flow is $1.95 M
What is Adaptimmune Therapeutics TTM FCF year-on-year change?
Over the past year, ADAP TTM free cash flow has changed by +$75.59 M (+57.42%)